NEJM:左主干冠脉疾病PCI或CABG后的五年结局

2019-11-07 xing.T MedSci原创

由此可见,在中度或中度复杂性的左主干冠状动脉疾病患者中,PCI组和CABG组5年时死亡、卒中或心肌梗塞的综合结局发生率无显著差异。

与左冠状动脉旁路移植术(CABG)相比,当代药物洗脱支架经皮冠状动脉介入治疗(PCI)的长期结果尚不清楚。

近日,顶级医学期刊NEJM上发表了一篇研究文章,研究人员随机分配了1905例低或中等解剖复杂程度(根据参与中心的评估)的左冠状动脉疾病患者接受含氟聚合物钴铬铬依维莫司洗脱支架的PCI(PCI组,948例患者)或CABG(CABG组,957例)。该研究的主要结局是死亡、卒中心肌梗死的综合结局。

在5年时,PCI组22.0%的患者和CABG组19.2%的患者发生了主要结局事件(差异为2.8 个百分点;95%置信区间[CI]为-0.9至6.5;P=0.13)。与CABG组相比,PCI组死于任何原因的发生率更高(分别为13.0%和9.9%;差异为3.1个百分点;95%CI为0.2至6.1)。在PCI和CABG组中,确定性心血管死亡(分别为5.0%和4.5%;差异为0.5个百分点;95%CI为-1.4至2.5)和心肌梗死(分别为10.6%和9.1%;差异为1.4个百分点;95%CI为-1.3至4.2)的发生率没有显著差异。尽管卒中的发生率在两组之间没有显著差异(分别为2.9%和3.7%;差异为-0.8个百分点;95%CI为-2.4至0.9),但PCI后所有脑血管事件的发生率均低于CABG组(3.3% vs. 5.2%;差异为-1.9个百分点;95%CI为-3.8至0)。PCI后缺血性血运重建术比CABG后更为频繁(16.9% vs. 10.0%;差异为6.9个百分点;95%CI为3.7至10.0)。

由此可见,在中度或中度复杂性的左主干冠状动脉疾病患者中,PCI组和CABG组5年时死亡、卒中或心肌梗塞的综合结局发生率无显著差异。 

原始出处:

Gregg W. Stone, et al.Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.NEJM.2019.https://www.nejm.org/doi/full/10.1056/NEJMoa1909406

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718543, encodeId=b4141e1854391, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Thu Apr 16 04:04:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572985, encodeId=31b415e2985ea, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Fri Nov 08 23:04:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035008, encodeId=63c510350089e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Nov 07 11:04:00 CST 2019, time=2019-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718543, encodeId=b4141e1854391, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Thu Apr 16 04:04:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572985, encodeId=31b415e2985ea, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Fri Nov 08 23:04:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035008, encodeId=63c510350089e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Nov 07 11:04:00 CST 2019, time=2019-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718543, encodeId=b4141e1854391, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Thu Apr 16 04:04:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572985, encodeId=31b415e2985ea, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Fri Nov 08 23:04:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035008, encodeId=63c510350089e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Nov 07 11:04:00 CST 2019, time=2019-11-07, status=1, ipAttribution=)]
    2019-11-07 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0